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BACKGROUND. Specific mutations of the p53 tumor suppressor gene in hepatocel-
lular carcinoma (HCC) have been reported from several parts of the world, but to
the authors’ knowledge to date the status of this gene has not been studied in HCC
patients in India, where HCC is one of the major cancers and the frequency of
chronic hepatitis B virus (HBV) as well as hepatitis C virus (HCV) infection and
exposure to dietary aflatoxin B1 is very high. The most frequent mutation of the p53
gene in HCC is an AGGArg to AGTSer missense mutation at codon 249 of exon 7.
METHODS. Liver biopsy specimens from 21 HCC patients and 10 healthy controls
were obtained through surgery or by needle biopsy technique. Phenol-chloroform-
extracted DNA specimens were employed for the detection of HBV infection and
p53 gene mutations. Nucleotide mutations of exons 4 –9 of the p53 gene were
analyzed by polymerase chain reaction (PCR), single strand confirmation polymor-
phism, and direct sequencing. Third-generation sandwich enzyme-linked immu-
nosorbent assay (ELISA) was used for the serologic detection of HBV and HCV
infection.
RESULTS. Analysis of exons 4 –9 of the p53 gene revealed only 3 mutations (3 of 21
specimens, 14.28%; 95% confidence interval, 20.7–29.3), 2 mutations at codon 249
showing G3T transversions, and 1 mutation (4.7%) at codon 250 with a C3T
transition. The base substitutions at the third base of codon 249 resulted in a
missense mutation leading to a change in amino acid from arginine to serine
whereas at codon 250 it caused a change from proline to serine. Dot blot hybrid-
ization and PCR for HBV DNA from HCCs revealed 58.8% (10 of 17 specimens) and
90.47% (19 of 21 specimens), positivity, respectively. ELISA for hepatitis B virus
surface antigen in serum showed a positivity of 71.42% (15 of 21 specimens), but
there was only 40% positivity (8 of 20 specimens) for hepatitis B virus envelope
antigen whereas 6 of 17 patients (35.29%) showed the presence of antibodies
against hepatitis B virus envelope protein. No patient was found to be positive for
the HCV antibody.
CONCLUSIONS. The very low frequency of p53 mutations and the extremely high
frequency of HBV infection (. 90%) in HCC indicate that the mutations in the p53
gene frequently found in HCC reported from different endemic areas of the world
may not play a direct role in the development of HCC in India. HBV infection and,
possibly, exposure to the dietary aflatoxin B1 appear to play major roles in the
molecular pathogenesis of HCC in India. Cancer 2000;88:1565–73.
© 2000 American Cancer Society.
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Hepatocellular carcinoma (HCC) is one of the most prevalent can-cers in the world, particularly in Southeast Asia and Africa includ-
ing Japan.1–5 In India, human hepatocellular carcinoma is one of the
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major cancers in both genders along with cervical
carcinoma in women. Epidemiologic studies have es-
tablished that chronic infection of hepatitis B virus
(HBV) and to a certain extent hepatitis C virus (HCV)
and exposure to dietary aflatoxin B1 and intake of
alcoholic beverages are important risk factors for the
development of HCCs.6 –12 However, the precise mo-
lecular mechanisms of liver carcinogenesis still are not
clearly understood.
Recently, specific mutations of p53 tumor sup-
pressor gene have strongly been implicated in a vari-
ety of human cancers, and the majority of them is
located in the highly conserved regions of the gene,
which are involved in DNA binding and transcrip-
tional activation.13 Wild-type p53 gene acts as a tumor
suppressor as it plays a central role in regulating tran-
scriptional activation of crucial growth regulatory
genes that control cell cycle progression and cell divi-
sion. Mutations of the p53 gene abrogate its normal
function leading to genomic instability and loss of
growth control.14 The loss of heterozygosity and ab-
normalities in structure and function of the p53 gene
are frequent in HCCs. Specific base substitutions par-
ticularly G3 T transversion at third position of codon
249 (AGG) of the p53 gene results in replacement of
arginine with serine. This is the most common muta-
tional “hot spot” found in HCCs in more than 50% of
cases reported from different geographic regions, such
as, China and southern Africa, where dietary aflatoxins
are suspected to be the major liver specific carcino-
gens that cause p53 mutation.5,13,15–18 Indeed, in vitro
experiments have shown that aflatoxin B1 can induce
G:C to T:A transversion at codon 249.19,20 Even the
noncancerous liver tissues from these high aflatoxin
exposed areas were found to harbor mutations in
codon 249.21 In contrast, absence or low aflatoxin
exposures in countries like Japan, the United States,
and Australia showed such mutational hot spots at
codon 249 in only 0 to 26% of HCCs.13,22–24 Recently, it
also has been reported that HBV or HCV infection
alone can induce the carcinogenic pathways causing
p53 abnormalities other than codon 249.18
Hepatitis B virus infections are seen in 3–7% of the
general population in India25,26 in which dietary As-
pergillus contamination is also very high.27,28 There-
fore, for a vast country such as India where both HBV
infection and aflatoxin contamination of food are
most prevalent, it is interesting to look for abnormal-
ities of p53 gene in general and its codon 249 in
particular because there is to our knowledge no infor-
mation on the status of p53 gene mutation in HCC
patients in India. Here, we report that the frequency of
p53 mutation is considerably low, but the prevalence
of hepatitis B virus infection is exclusively high in
Indian patients with hepatocellular carcinoma.
MATERIALS AND METHODS
Patients and Tissue Specimens
Liver biopsy specimens from 21 hepatocellular carci-
noma patients and 10 controls were obtained at sur-
gery (15 patients) or by needle biopsy technique (6
patients) from Department of Gastroentrology, G.B.
Pant Hospital in New Delhi. The patients included 19
males and 2 females, age 10 – 68 years, all belonging to
high aflatoxin exposure regions of northern India. The
control subjects were between the age of 29 and 65
years (male:female ratio, 5:5), and all had undergone
abdominal surgery for unrelated causes (gallstone dis-
ease; 4 patients, intestinal obstruction; 3 patients,
peptic ulcer; 3 patients). The 10 control patients were
initially tested for liver disease but proved to have
normal livers after histologic analysis.
No patient had undergone chemotherapy before
tumor excision. Histologic tumor grading was done
according to Edmondson and Steiner.29 Tissue biop-
sies were stored in 270 °C until analysis. Informed
consent was obtained from all the patients before
biopsies were conducted.
Extraction of Genomic DNA
All HCC specimens included in the study were exam-
ined under a dissecting microscope to exclude normal
tissue and to obtain only the tumor tissues for extrac-
tion of genomic DNA. High molecular weight genomic
DNA was isolated from HCC and control liver tissues
by standard proteinase K digestion and phenol-chlo-
roform extraction as described previously30
Polymerase Chain Reaction for p53 and HBV
DNA (100 –200 ng) was amplified by polymerase chain
reaction (PCR) by using DNA thermal cycler (Perkin-
Elmer Cetus, Norwalk, CT). Oligonucleotide primer
sequences used to amplify p53 gene exons 4 –9 and
HBV core gene (Table 1) were designed and synthe-
sised in an ABI 381A DNA Synthesiser (Applied Bio-
systems, Foster City, CA) and purified by a reverse
phase high-performance liquid chromatography
(Schmadzu, Kyoto, Japan). Polymerase chain reaction
amplification was performed in 25 mL reaction volume
containing 10 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5
mM MgCl2, 125 mM of each dNTP (dATP, dCTP, dGTP,
dTTP), 5 pmoles of each oligonucleotide primer, and
0.5 U Taq DNA polymerase (Perkin-Elmer Cetus). The
temperature profile followed for amplification of p53
exons was initial denaturation at 95 °C for 5 minutes
followed by 35 cycles of 95 °C for 30 seconds, 55 °C for
20 seconds, and 72 °C for 20 seconds, and a final
1566 CANCER April 1, 2000 / Volume 88 / Number 7
extended synthesis at 72 °C was performed for 5 min-
utes. For amplification of HBV DNA sequences, initial
denaturation at 95 °C was for 5 minutes followed by 40
cycles, each consisting of denaturing at 95 °C for 30
seconds, annealing at 51 °C for 50 seconds and exten-
sion at 72 °C for 50 seconds, but a final synthesis at
72 °C was extended for 10 minutes. The amplified
products were visualized on an ethidium bromide-
stained 3% NuSieve agarose (FMC Bioproducts, Rock-
land, ME) gel under a ultraviolet light transillumina-
tor.
HaeIII Digestion of p53 Exon 7 Amplimers
For analysis of p53 gene mutation, particularly at
codon 249, Hae III digestion of PCR products of exon
7 was performed. The 249th codon in the p53 gene is
a mutation hot spot specific for HCCs. A mutational
change either at the second or at the third nucleotide
in this codon often results in abolition of restriction
site for Hae III.31
After amplification of exon 7 in tumor DNA by
PCR and electrophoresis of 125-base pair (bp) PCR
products, the bands were excised from the gel and
eluted by centrifugation or by diethyl amino-ethyl
(DEAE) ion exchange membrane method. DNA was
precipitated overnight at 220 °C by addition of one-
tenth volume of 3 M sodium acetate (pH 5.0) and 2.5
volumes of chilled ethanol. After centrifugation, the
pellet was resuspended in 10 mL tris-EDTA (TE) buffer
and digested in 20 mL reaction volume containing 10
U of Hae III enzyme (Boehringer Mannheim, Mann-
heim, Germany). The resultant digests were electro-
phoresed in ethidium bromide-stained 3% NuSieve
agarose (FMC Bioproducts) gels and observed for ab-
olition of restriction site.
Single Strand Conformation Polymorphism
Single strand conformation polymorphism (SSCP)
analysis was performed by radiolabeling the PCR
products for an additional 15 cycles by using 1mCi of
a32P dCTP (Bhabha Atomic Research Centre, Trom-
bay, Bombay, India) and cycling each at 95 °C for 30
seconds, 55 °C for 20 seconds, and 72 °C for 20 sec-
onds. One microliter of the labeled product was di-
luted with 10 volumes of denaturing solution contain-
ing 95% formamide, 20 mM EDTA (pH 8.0), 0.05%
xylene cyanol, and 0.05% bromophenol blue and heat-
denatured for 5 minutes at 95 °C and chilled on ice for
5 minutes. Three microliters of this product was sub-
jected to nondenaturing electrophoresis in a 6% poly-
acrylamide sequencing gel run in 0.5 3 tris-borate-
EDTA (TBE). The gel was run for 12 hours at 200 V in
Base Ace sequencing gel apparatus (Stratagene
GmbH, Heidelberg, Germany) at 17 6 1 °C, dried, and
exposed to X-ray film at 270 °C. Alterations in elec-
trophoretic mobility shift in single strand DNA bands
were analyzed in comparison to that of normal con-
trols.
TABLE 1
Oligonucleotide Primer Sequences Used for PCR Amplification of Different Exons of p53 Gene and HBV DNA
Primer Nucleotide position in genomic DNA Amplified fragment (bp) Primer sequencesa
p53 exon 4 12041–12063 259 (1)59-AAT GGA TGA TTT GAT GCT GTC CC-39
12279–12299 (2)59-CGT GCA AGT CAC AGA CTT GGC-39
Exon 5 13055–13074 184 (1)59-TAC TCC CCT GCC CTC AAC AA-39
13219–13238 (2)59-CAT CGC TAT CTG AGC AGC GC-39
p53 exon 6 13320–13339 113 (1)59-GTC TGG CCC CTC CTC AGC AT-39
13413–13432 (2)59-CTC AGG CGG CTC ATA GGG CA-39
p53 exon 7 13992–14012 125 (1)59-TCT CCT AGG TTG GCT CTG ACT-39
14096–14116 (2)59-TCC TGA CCT GGA GTC TTC CAG-39
p53 exon 8 14452–14471 87 (1)59-TGG TAA TCT ACT GGG ACG GA-39
14519–14538 (2)59-CGG AGA TTC TCT TCC TCT GT-39
p53 exon 9 14666–14685 104 (1)59-TTG CCT CTT TCC TAG CAC TG-39
14750–14769 (2)59-CCC AAG ACT TAG TAC CTG AA-39
HBV 2269–2286 147 (1)59-GGA GTG TGG ATT CGC ACT-39
2415–2398 (2)59-TGA GAT CTT CTG CGA CGC-39
PCR: polymerase chain reaction; HBV: hepatitis B virus; bp: base pair.
a (1): sense primer; (2): antisense primer.
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DNA Sequencing
DNA sequencing was performed on those PCR prod-
ucts that showed altered band mobility in SSCP anal-
ysis along with more than 50% of other HCC DNA
samples. Fresh PCR products were prepared by PCR
amplification of original tumor DNA and purified by
using Qiagen PCR purification columns (Qiagen
GmbH, Hilden, Germany). Nucleotide sequences were
determined by using a modification of the Sanger et al.
dideoxy chain termination method32 with Sequenase
version 2.0 (Amersham/United States Biochemicals,
Cleveland, OH) and a32P dATP (Bhabha Atomic Re-
search Centre). For sequencing with Sequenase, the
PCR products were first cloned in Promega Easy A-T
Cloning System (Promega, Madison, WI). When the
amount of template DNA was much less, we used
double-stranded cycle sequencing method using Cy-
clist exo2 Pfu sequencing kit (Stratagene GmbH).
Serologic Enzyme-Linked Immunosorbent Assay Tests
Serologic enzyme-linked immunosorbent assay (ELISA)
was performed in serum samples collected from the
HCC patients. Serologic tests for serum HBsAg, hepa-
titis B virus envelope antigen (HBeAg), and antibodies
against hepatitis B virus envelope antigen (Anti-HBe)
were performed using sandwich ELISA technique (Or-
ganon Teknika, Boxtel, The Netherlands) and anti-
HCV by third generation sandwich ELISA (United
Biomedical Inc., Hauppauge, NY) for detection of
hepatitis B and hepatitis C virus infection, respec-
tively.
RESULTS
The age, gender, histopathologic grading, and results
of viral DNA positivity and serologic ELISA for 21
hepatocellular carcinoma patients are presented in
Table 2. Histologic grading29 done on the basis of
nucleic acid atypia, chromatin content, and the size or
multiplicity of the nucleus of tumor tissue biopsies
identified 11 cases in Stage I, 7 to Stage II, and 3 to
Stage III. Dot blot hybridization of genomic DNA ex-
tracted from hepatocellular carcinomas with HBV spe-
cific probe (3.2 kilobase pairs)33 revealed 58.8% (10 of
17) whereas the same samples when subjected to PCR
for HBV DNA revealed 90.47 % (19 of 21) positivity
(Fig. 1). The PCR products also were reconfirmed by
Southern blot hybridization procedure with certain
modifications34,35 by using HBV DNA probe (figure
TABLE 2
Age, Gender, Histologic Grading, HBV DNA Positivity, and Its Serologic Profile and p53 Mutations of HCC Patients
Patient
no. Gender Age (yrs)
Origin of
specimen Stage
HBV DNA Assays in serum
p53 mutationsDot blot PCR HBsAg HBeAg Anti-HBe HCV
1 F 48 Surgery I 2 1 1 1 2 2 2
2 M 10 Surgery I 1 1 1 2 1 2 2
3 M 55 Surgery I 2 1 2 2 2 2 2
4 M 44 Surgery I 1 1 1 2 1 2 2
5 M 60 Surgery II 2 2 1 1 2 2 2
6 F 45 Surgery II 2 2 1 1 2 2 2
7 M 28 Surgery II 2 1 2 1 2 2 2
8 M 28 Surgery II 1 1 1 1 2 2 2
9 M 55 Surgery III 1 1 1 1 1 2 1
10 M 40 Surgery I 1 1 1 1 1 2 2
11 M 67 Surgery III 1 1 1 2 1 2 2
12 M 54 Needle I 2 1 1 2 2 2 2
13 M 45 Needle I 1 1 1 2 1 2 2
14 M 40 Needle I ND 1 2 2 2 2 2
15 M 45 Surgery III 2 1 2 2 ND 2 1
16 M 53 Surgery I 1 1 1 2 2 2 1
17 M 55 Needle I ND 1 1 2 ND 2 2
18 M 68 Surgery II ND 1 2 ND ND 2 2
19 M 52 Surgery II ND 1 2 2 ND 2 2
20 M 42 Needle I 1 1 1 1 2 2 2
21 M 45 Needle II 1 1 1 2 2 2 2
Total 10/17 (58.88) 19/21 (90.47) 15/21 (71.42) 8/20 (40) 6/17 (35.29) 0 3/21 (14.28)
(95% CI, 20.7–29.3)
HBV: hepatitis B virus; HCC: hepatocellular carcinoma; PCR: polymerase chain reaction; HBsAg: hepatitis B virus surface antigen; HBeAg: hepatitis B envelope antigen; Anti-HBe: antibodies against hepatitis B virus
envelope antigen; HCV: hepatitis C virus; F: female; M: male; ND: not done.
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not shown). To our knowledge, this is a first PCR
estimate of HBV frequency in HCC patients in India.
None of the ten normal controls showed presence of
HBV DNA by either dot blot or PCR. ELISA for hepa-
titis B virus surface antigen (HBsAg) in serum showed
71.42% (15 of 21) positivity, but there was only 40% (8
of 20) positivity for hepatitis B virus envelope antigen
(HBeAg) whereas 6 out of 17 patients (35.29%) showed
presence of Anti-HBe. No patient was found to be
positive for HCV antibody.
PCR amplification of exons 4 –9 of the p53 gene
resulted in amplimers of sizes 259, 184, 113, 125, 87,
and 104 bp, respectively, in all tumor biopsies. Figure
2a,b shows a representative PCR amplification of the
exons 7 and 8, respectively. To check the mutation
specifically at codon 249, Hae III restriction digestion
of PCR products of exon 7 was performed. Only one
sample showed absence of digestion indicating pres-
ence of p53 mutation at its codon 249 that also was
confirmed by DNA sequencing. All other amplimers
were completely digested with the Hae III restriction
enzyme thereby producing the digestion products of
83 and 42 bp (Fig. 3).
Analyses of all the above p53 exons by SSCP re-
vealed presence of only three mutations (14.28%, 3 of
21; 95% CI, 20.7–29.3) in exon 7 (Table 3) as indicated
by a shift in electrophoretic mobility in single stranded
DNA bands on 6% polyacrylamide nondenaturing gels
(Fig. 4). In addition, the samples showing doubtful
mobility shifts in SSCP also were sequenced. All of
them except three showed altered DNA sequence
when compared with the sequence obtained from
DNA sequencing of normal liver tissue specimens.
Interestingly, no mutation could be detected in exons
4 – 6 and 8, and 9 of the p53 gene. Nucleotide sequenc-
ing of the PCR products showing altered electro-
FIGURE 1. Polymerase chain reaction amplification of hepatitis B virus (HBV)
DNA showing amplimer size of 147 base pair (bp) (arrow) is shown. Lane 1:
positive control of HBV plasmid DNA; Lane 2: negative control (placental DNA);
Lanes 3–12: represent results of amplification from hepatocellular carcinoma
DNA samples of which Lanes 7 and 8 were negative for HBV DNA. M: Hae III
digested FX174 DNA molecular weight marker.
FIGURE 2. Polymerase chain reaction amplification of exons 7 and 8 of p53
gene in hepatocellular carcinoma (HCC) and control liver biopsy DNA samples
showing (a) amplimer size of 125 base pair (bp) in exon 7 and (b) 87 bp in exon
8. In both the panels, Lanes 1 and 2 are control DNA samples whereas Lanes
3–9 are HCC DNA samples that show specific amplification of desired size of
amplimers for exons 7 and 8 of the p53 gene. M: HaeIII digested specific
FX174 DNA molecular weight marker.
FIGURE 3: Hae III restriction enzyme digestions of p53 polymerase chain
reaction products of p53 exon 7 amplimer (125 base pair [bp]) that show two
distinct bands, 83 bp and 42 bp, respectively, indicating absence of a 249
codon mutation. pGEM: DNA molecular weight marker.
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phoretic mobility in SSCP along with normal controls
(Fig. 5a) showed transversion of the third base at
codon 249 from AGG to AGT (Fig. 5c) in two samples
whereas at codon 250, it was a transition of CCC to
TCC (Fig. 5b). These base substitutions at the third
base (G3T) of the codon 249 resulted in a missense
mutation leading to change of amino acid, arginine to
serine, whereas at codon 250, it resulted in a change of
proline to serine (see Table 3).
Of the two patients who showed mutations in
codon 249, one (Patient 9) was shown to be positive
for HBsAg as well as HBeAg by ELISA and also shown
to be positive for HBV DNA by dot blot hybridization
as well as PCR whereas the second patient (patient 15)
was negative for HBsAg, HBeAg, and Anti-HBeAg but
positive for HBV DNA by PCR. Both these patients
were in late stage of cancer (Stage III). The lone case
who showed mutation at codon 250 was found to be in
Stage I and was positive for both HBsAg and HBV
DNA.
DISCUSSION
p53 gene mutation is one of the most common events
in human carcinogenesis, and approximately 90% of
its mutations are of the missense type.36 The profile of
p53 gene mutations differs in different types and
grades of liver carcinoma that have been associated
with several other factors such as infection of HBV or
HCV, exposure to aflatoxins, and genetic constitution
or ethinicity of a population including certain cultural
habits.13,22 p53 mutations also have been reported to
differ in HCCs from different geographic regions. It
has been demonstrated that the most common muta-
tion in HCCs is at codon 249, which is causally related
to high aflatoxin B1 exposure.
15,37 G:C to T:A transver-
sions are the most common base substitutions ob-
served in bacteria, in HCC patients and in in vitro
experiments after exposure to aflatoxin B1.
21,38 So far
no analysis of p53 mutations in HCC patients in India
has been reported. In the current study, analysis of 21
HCCs revealed a very low frequency (9.5%; 95% CI,
23.0 –22.1) of p53 gene mutations at codon 249, the
most common mutational hot spot in HCCs. A low
frequency of p53 mutations involving codon 249 also
have been reported in Germany,23 Taiwan,39 and Thai-
land,40 but the rate of mutation is certainly higher
than what has been observed in India. Interestingly,
no mutation could be detected in any of the other
highly conserved exons (4 –9) except only in exon 7,
which has been found to be mutated in only 3 patients
(14.2%; 95% CI, 20.7–29.3) , a prevalence that is much
lower than that reported from other low-prevalence
countries.15,16,24 This specific 249 codon mutation was
also reconfirmed by the Hae III restriction enzyme
digestion test,31 which showed similar results. It is
noteworthy because in 14 most common food com-
modities used in the states of India including the
northern states from where the patients lived, the level
of aflatoxin B1 exceeded the Prevention of Food Adul-
teration limit of 30 mg/Kg2.127,28 This is in contrast to
the observation that southern Africa and Qidong prov-
ince in China where aflatoxin exposure is high, the
rate of p53 gene mutation is also very high at the third
base of codon 249. Several other authors16,17 have
achieved similar results. But in other parts of the world
such as Australia, Japan, Germany, North Korea, The
United States, and France where the dietary aflatoxin
TABLE 3
Mutations of the p53 Gene as Revealed by PCR-SSCP and Sequencing in Hepatocellular Carcinomas in India
Patient no.
Mutation detected at
Nucleotide change Amino acid change Type of mutationExon Codon
9 7 249 AGG3AGT Arg3Ser Transversion
15 7 249 AGG3AGT Arg3Ser Transversion
16 7 250 CCC3TCC Pro3Ser Transition
PCR: polymerase chain reaction; SSCP: single strand conformation polymorphism.
FIGURE 4: Polymerase chain reaction-single strand conformation polymor-
phism analysis of p53 gene mutation in hepatocellular carcinoma patients. PCR
amplified 125-base pair fragments that encompass exon 7 of the p53 gene
were electrophoresed on 6% polyacrylamide nondenaturing sequencing gels.
Cases positive for mutation show different mobility shifts (arrows). Of the ten
samples (Lanes 1–10), abnormal mobility shift was observed in Lanes 1 and 5.
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content is very low or nil, the mutation at codon 249 is
also found to be rare or absent.41 Although in places
such as Beijing where exposure to aflatoxin is low,
there is absence of mutation at codon 249, but a high
rate of mutations (56%) at other codons was observed.
However, this has not been observed in the current
study that indicates that factors other than AFB or
AFB-induced p53 mutations may be responsible for
development of HCCs in India.
Although no particular etiologic agent has been
identified for the development of hepatocellular car-
cinoma, infection and integration of HBV into the host
cell genome42 and partly also infection of HCV are
considered to be the prime causative factors for HCCs
in different parts of the world.43 In the current study,
although no patient was found to be infected with
HCV, more than 90% of HCCs (19 out of 21) were
positive for HBV DNA. The serologic detection of HB-
sAg, which is considered to be the definitive marker of
an active viral replication and infectivity, also revealed
more than 70% positivity (see Table 2). This is an
extremely high prevalence of HBV ever reported for
HCCs from other parts of the world.44,45 The three
patients who carried p53 mutations had been or were
infected with HBV. These findings suggest that infec-
tion with HBV is the major etiologic agent, and possi-
bly an interaction between HBV and aflatoxin B1 could
be responsible for the development of hepatocellular
carcinoma in India. Furthermore, it has been sug-
gested that HBV integration in the host cell genome
may lead to interruption of growth regulatory genes
and integration-mediated chromosome losses or spe-
cific allele losses, which may affect p53 gene function
and viral transactivation.12,46,47 It is also suggested that
HBV-induced inflammatory process may influence se-
lective 249 codon mutation.48 Recently, it has been
demonstrated that the hepatitis B virus transcriptional
transactivating protein, HBX, which is essential for
viral infection, is also implicated in liver carcinogen-
esis. HBX can bind to p53 protein49 –51 and inhibits
sequence specific DNA binding and p53-mediated
transcriptional transactivation activities. As p53 gets
inactivated by binding with oncogene products of
other DNA tumor viruses.52 HBX protein also can bind
with p53 to inactivate it, and this may facilitate hepatic
damage by carcinogenic agents. It has been shown
further that by activating the binding of the specific
RNA polymerase II transcription factor, AP-1,53,54 the
hepatitis B virus protein HBX stimulates Ras-GTP
complex and activates the Ras-Raf mitogen activated
protein kinase signal transduction pathways, which
may influence liver cell proliferation.49
Occurrence of a low frequency of p53 mutation at
codon 249 in Indian patients may also be attributed to
other factors such as ethinic variations in susceptibil-
ity to aflatoxin B1. Aflatoxin B1 is metabolized to its
carcinogenic forms by a group of enzymes called cy-
tochrome P450, the level of which may vary in different
populations.55 In addition, there exists polymor-
phisms and ethinic variations in carcinogen detoxify-
ing enzymes such as glutathione S-transferase mu 1
and epoxide hydrolase, which play an important role
in detoxification of aflatoxins in humans.56,57
Because carcinogenesis is a multistep process and
because the exact role of individual carcinogenic
agent is not clear, the interaction of host cell factors
along with viral and chemical carcinogens appears to
play a key role in the development of hepatocellular
carcinoma in humans. Furthermore, the use of PCR
provides an effective complementation to serologic
ELISA for a reliable estimate of HBV infection.
FIGURE 5. Direct DNA sequencing of
polymerase chain reaction amplified
fragments (125 base pair) of exon 7 of
the p53 gene in hepatocellular carci-
noma that showed mobility shift in sin-
gle strand conformation polymorphism
(lanes 1 and 7 in Fig. 2). A CCC to TCC
transition was found at codon 250 (b)
whereas a AGG to AGT transversion was
observed in codon 249 (c). DNA of con-
trol patient (a) shows normal DNA se-
quence pattern of exon 7 of the p53
gene.
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